{"1":{"dur":2,"text":"My name is Gayatri Rao\nand I'm the Director for"},"3":{"dur":2,"text":"the Office of Orphan\nProducts Development at"},"5":{"dur":1,"text":"FDA."},"6":{"dur":2,"text":"My office's mission is to\npromote the development of"},"9":{"dur":3,"text":"products like drugs,\nbiologics, devices, and"},"12":{"dur":3,"text":"medical foods for patients\nwith rare diseases."},"16":{"dur":3,"text":"One very common stumbling\nblock in rare disease drug"},"19":{"dur":2,"text":"development is that we\ndon't know enough about"},"22":{"dur":2,"text":"the natural history of\nthe rare disease being"},"24":{"dur":1,"text":"studied."},"26":{"dur":2,"text":"Without having a solid\nunderstanding of how a"},"28":{"dur":3,"text":"disease progresses and\nwhat the disease's natural"},"32":{"dur":3,"text":"clinical course is, it\nbecomes very difficult to"},"35":{"dur":2,"text":"develop a drug and\nevaluate whether it is"},"38":{"dur":2,"text":"safe and effective."},"40":{"dur":2,"text":"Patients and patient\nadvocacy groups can play a"},"43":{"dur":2,"text":"critical role in\ndeveloping this vital"},"46":{"dur":3,"text":"information, because\nthey're motivated well"},"49":{"dur":2,"text":"organized and have strong\nnetwork within the patient"},"52":{"dur":1,"text":"community."},"53":{"dur":1,"text":"Typically, the only\nthing that prevents"},"55":{"dur":2,"text":"organizations like patient\nadvocacy groups from"},"58":{"dur":3,"text":"conducting a natural\nhistory study is funding."},"62":{"dur":2,"text":"To help fill this gap, I'm\nvery excited to announce"},"65":{"dur":2,"text":"that my office will be\nlaunching a new grant"},"68":{"dur":3,"text":"program to fund targeted\nrare disease natural"},"71":{"dur":2,"text":"history studies that will\nmeaningfully inform and"},"74":{"dur":2,"text":"guide product development\nfor rare diseases, whether"},"77":{"dur":4,"text":"it be the development of\ndrugs, biologics, devices"},"81":{"dur":1,"text":"or medical foods."},"83":{"dur":2,"text":"The program is generally\nopen to all applicants,"},"86":{"dur":3,"text":"including patient advocacy\ngroups, academicians and"},"90":{"dur":1,"text":"industry."},"91":{"dur":2,"text":"We plan to fund studies\nwith the best scientific"},"93":{"dur":2,"text":"merit, which can include\nprospective studies,"},"96":{"dur":3,"text":"retrospective studies\nand survey type studies."},"99":{"dur":3,"text":"More information about\nthis new grant program,"},"103":{"dur":2,"text":"along with contact\ninformation, can be found"},"105":{"dur":3,"text":"on our website at<u>\nwww.fda.gov\/orphan<\/u>"},"109":{"dur":1,"text":"<u><http:\/\/www.fda.gov\/orphan<\/u>"},"111":{"dur":1,"text":"<u>><\/u> ."},"112":{"dur":3,"text":"In conjunction with the\nlaunch of our new natural"},"115":{"dur":2,"text":"history grant program,\nwe have developed the"},"118":{"dur":2,"text":"following webinar to\nprovide some basic"},"120":{"dur":3,"text":"information about natural\nhistory studies, what they"},"124":{"dur":3,"text":"are, why they're important\nand how you, as a patient"},"127":{"dur":3,"text":"or a patient advocate, can\nmake a real difference."},"130":{"dur":2,"text":"Hi, my name is\nRichard Klein."},"133":{"dur":3,"text":"I'm the Director of the\nPatient Liaison Program at"},"136":{"dur":1,"text":"the Food and Drug\nAdministration's Office of"},"138":{"dur":2,"text":"Health and\nConstituent Affairs."},"140":{"dur":2,"text":"Our office is the primary\npoint of contact for"},"143":{"dur":2,"text":"patients and patient\nadvocacy organizations."},"146":{"dur":3,"text":"And it's my pleasure to\nbe the moderator for this"},"149":{"dur":2,"text":"important discussion on\nnatural history studies"},"151":{"dur":1,"text":"for rare diseases."},"153":{"dur":3,"text":"I'm joined in the studio\nby Tim Frost, a patient"},"157":{"dur":4,"text":"with Alpha-1 Antitrypsin\nDeficiency; Gayle Greene"},"161":{"dur":2,"text":"is a caregiver for\nfamily members with Von"},"163":{"dur":3,"text":"Hippel-Lindau Syndrome;\nDr. Theresa Strong is"},"167":{"dur":2,"text":"Director of the Research\nPrograms at the Foundation"},"170":{"dur":2,"text":"for Prader-Willi Research,\nand from the Food and Drug"},"173":{"dur":2,"text":"Administration Center\nfor Drug Evaluation and"},"176":{"dur":3,"text":"Research, Dr. Andrew\nMulberg, Deputy Director"},"180":{"dur":2,"text":"of the Division of\nGastroenterology and"},"182":{"dur":3,"text":"Inborn Errors Products,\nand Dr. Jonathan"},"186":{"dur":2,"text":"Goldsmith, Associate\nDirector for the Rare"},"188":{"dur":1,"text":"Diseases Program."},"189":{"dur":2,"text":"Welcome everyone."},"192":{"dur":2,"text":"I think probably the best\nplace to start is the"},"194":{"dur":3,"text":"definition and the\nexpansion of what is a"},"198":{"dur":1,"text":"natural history study."},"199":{"dur":2,"text":"Jonathan, probably you're\nthe best person to answer"},"201":{"dur":0,"text":"that question."},"202":{"dur":1,"text":"Thanks."},"204":{"dur":3,"text":"Well, natural history\nstudy is a well-designed,"},"207":{"dur":3,"text":"well-thought out, and\nwell-planned attempt to"},"210":{"dur":2,"text":"learn about what happens\nto people who are affected"},"213":{"dur":2,"text":"by a particular\nspecific rare disease."},"216":{"dur":4,"text":"So you try to collect data\nthat really is obtained"},"220":{"dur":4,"text":"early in the course of the\ndisease, later on in the"},"225":{"dur":1,"text":"course of the disease\nwhen people may become"},"227":{"dur":3,"text":"symptomatic, when they may\nactually progress to have"},"230":{"dur":3,"text":"symptoms and without\nintervention they might"},"234":{"dur":4,"text":"get better spontaneously,\nthey might not get better"},"238":{"dur":1,"text":"or they might die\nfrom a disease."},"240":{"dur":2,"text":"So a natural history study\nis trying to capture"},"242":{"dur":2,"text":"people at all those\ndifferent parts of time in"},"245":{"dur":4,"text":"a way that uses uniform\nmedical terms so that the"},"249":{"dur":4,"text":"information can be used\nlater on by scientists and"},"254":{"dur":2,"text":"investigators, as well as\nby people at the Food and"},"257":{"dur":2,"text":"Drug Administration when\nthey begin to look at drug"},"260":{"dur":1,"text":"applications, they\ncan understand this"},"262":{"dur":1,"text":"information."},"264":{"dur":3,"text":"So is that different\nthan a patient registry?"},"267":{"dur":1,"text":"Yes, I think it is."},"269":{"dur":1,"text":"A registry could\nbe very simple and"},"271":{"dur":2,"text":"straightforward, like for\ninstance, a list of names"},"274":{"dur":3,"text":"and emails, so that a\nstakeholder organization,"},"278":{"dur":2,"text":"a patient advocacy group\nthat was trying to build"},"281":{"dur":2,"text":"up its organization might\ncreate a registry like"},"283":{"dur":1,"text":"that."},"285":{"dur":2,"text":"It tells you a lot about\npeople potentially who are"},"288":{"dur":2,"text":"interested in learning\nmore about the disease or"},"290":{"dur":2,"text":"being part of a\nlarge organization."},"293":{"dur":2,"text":"But it doesn't, it doesn't\ngive you much information"},"295":{"dur":3,"text":"about the disease process."},"298":{"dur":3,"text":"A lot of registries are\ncollected from health"},"301":{"dur":1,"text":"records."},"303":{"dur":2,"text":"And health records are now\nbroadly available, lots of"},"305":{"dur":3,"text":"electronic mechanics for\nus to get data from."},"308":{"dur":1,"text":"And they're not\nnecessarily aimed at your"},"310":{"dur":2,"text":"specific rare disease and\nthe information that we"},"313":{"dur":2,"text":"need to get about your\nspecific disease."},"315":{"dur":2,"text":"So registries kind of fall\ndown in some of these"},"318":{"dur":1,"text":"areas."},"319":{"dur":1,"text":"Even though they're well\nintentioned as a source of"},"321":{"dur":1,"text":"information, they may\nnot have the kind of"},"323":{"dur":5,"text":"information that really\nsupports critical"},"330":{"dur":1,"text":"scientific judgments that\nhave to be made about what"},"332":{"dur":0,"text":"goes on with your disease."},"333":{"dur":1,"text":"Registries can also be\ncollected as a part of"},"335":{"dur":0,"text":"clinical care again."},"336":{"dur":1,"text":"And so a lot of\nthe information is"},"338":{"dur":1,"text":"fragmentary."},"339":{"dur":1,"text":"And again, it's not really\na robust scientific"},"341":{"dur":2,"text":"database, which I\nthink is what clinical"},"344":{"dur":2,"text":"investigators, patient\nadvocacy groups and"},"347":{"dur":3,"text":"regulators all want out of\nhaving a natural history"},"350":{"dur":3,"text":"study."},"354":{"dur":3,"text":"So just to try to put it\nin some kind of context,"},"357":{"dur":5,"text":"Andrew at FDA, FDA's very\nconcerned with the outcome"},"362":{"dur":2,"text":"of clinical trials and I\nknow that natural history"},"365":{"dur":2,"text":"studies would feed into\nclinical trial studies."},"367":{"dur":2,"text":"Can you talk about how\nthey contribute and how"},"370":{"dur":3,"text":"they set up endpoint\nselection, for example?"},"373":{"dur":0,"text":"Sure."},"374":{"dur":3,"text":"I do want to also\nsupplement Jonathon's"},"377":{"dur":3,"text":"comments about registries\nfirst, in that there are"},"380":{"dur":2,"text":"some good examples of\nregistries that have been"},"383":{"dur":2,"text":"developed through clinical\ncare that have been"},"386":{"dur":2,"text":"standardized that\nhave been useful to"},"389":{"dur":2,"text":"Dr. Goldsmith's point\nabout it being useful for"},"391":{"dur":1,"text":"scientific investigations."},"393":{"dur":2,"text":"And the example, of\ncourse, that comes to mind"},"395":{"dur":3,"text":"is the cystic fibrosis\nregistry which has been a"},"398":{"dur":4,"text":"prime example, a model\nfor many, which has used"},"403":{"dur":3,"text":"declaration of clinical\ncare attributes in a very"},"407":{"dur":2,"text":"standardized way, as Dr.\nGoldsmith has pointed"},"409":{"dur":4,"text":"out to be critical and has\nbeen useful for us to be"},"414":{"dur":3,"text":"able to be part of the\ndrug development process."},"417":{"dur":3,"text":"With regards to natural\nhistory studies, as you"},"420":{"dur":2,"text":"point out, natural history\nstudies are an important"},"423":{"dur":3,"text":"component, almost a\nprerequisite before a drug"},"427":{"dur":3,"text":"development program should\nbe initiated for a rare"},"430":{"dur":1,"text":"disease."},"431":{"dur":4,"text":"A natural history study\nis critical to be able to"},"436":{"dur":2,"text":"serve in a\nnon-interventional way,"},"438":{"dur":2,"text":"provide an understanding\nof how that disease"},"441":{"dur":3,"text":"manifests in children,\nadults, in the patient"},"445":{"dur":1,"text":"population of interest."},"446":{"dur":3,"text":"And is critical for\nthe investigation to"},"450":{"dur":2,"text":"understand how we can\nassess the potential"},"452":{"dur":2,"text":"impact of future\ntherapeutic agents, as you"},"454":{"dur":3,"text":"point out, outcome\nassessments are important"},"458":{"dur":1,"text":"to understand how they can\nbe developed through the"},"460":{"dur":3,"text":"process of what patients\nare suffering from."},"464":{"dur":4,"text":"And that can be gleaned\nfrom a longitudinal"},"468":{"dur":1,"text":"natural history study."},"469":{"dur":2,"text":": So we know where rare\ndiseases, by definition,"},"472":{"dur":2,"text":"really don't have a lot of\npatients to work with in"},"474":{"dur":1,"text":"clinical trials."},"476":{"dur":3,"text":"Can natural history\nstudies serve as a control"},"480":{"dur":1,"text":"group?"},"481":{"dur":2,"text":": With the proper\nconsiderations and"},"484":{"dur":2,"text":"understanding of what's\nrequired, a natural"},"487":{"dur":1,"text":"history study can\npotentially serve as a"},"489":{"dur":1,"text":"historical control."},"490":{"dur":4,"text":"But it requires strict\nattention to the issues"},"495":{"dur":2,"text":"that Dr. Goldsmith and I\nand you have just talked"},"497":{"dur":2,"text":"about, which is the\nattention to matching"},"500":{"dur":3,"text":"populations and to\nstrictly ensuring that the"},"504":{"dur":3,"text":"data collected will be of\nvalue in a statistical and"},"507":{"dur":2,"text":"regulatory sensitive\nmanner to be served as a"},"510":{"dur":1,"text":"historical control."},"512":{"dur":2,"text":": One of the problems with\nhistorical controls is"},"514":{"dur":3,"text":"that the way that the data\nwas collected and the era"},"518":{"dur":3,"text":"when it was collected may\nbe quite different from"},"522":{"dur":2,"text":"what contemporary\nmedicine is all about."},"524":{"dur":2,"text":"For instance, diagnostics\nmay have been different 10"},"527":{"dur":1,"text":"or 15 years ago."},"529":{"dur":2,"text":"Supportive care may be\nquite different at that"},"531":{"dur":3,"text":"time - the actual\npotential treatment"},"535":{"dur":4,"text":"availabilities - so that a\nhistorical control is not"},"539":{"dur":3,"text":"always the best control\nfor what's going on."},"542":{"dur":3,"text":"I would think that the\nbest way to do a natural"},"546":{"dur":4,"text":"history study is to have\na prospectively planned"},"550":{"dur":2,"text":"trial and to collect\ndata so that it's"},"552":{"dur":2,"text":"contemporaneous, it's all\ncollected from the same"},"555":{"dur":2,"text":"people at the same time\nwhen hopefully the"},"557":{"dur":3,"text":"standard of care is pretty\nuniform and that it moves"},"561":{"dur":2,"text":"forward in time to see\nwhat the impacts are of"},"563":{"dur":2,"text":"your intervention\npotentially or to learn"},"566":{"dur":3,"text":"just what the background\npace of the disease is."},"569":{"dur":3,"text":": Theresa, I know that\nyou've been involved in"},"572":{"dur":4,"text":"these types of studies and\ncan you talk a little bit"},"577":{"dur":3,"text":"about what the patient\nadvocacy or patient role"},"581":{"dur":3,"text":"is in recruiting and\nretaining people, and how"},"584":{"dur":1,"text":"these studies are\naffecting patients who"},"586":{"dur":1,"text":"participate?"},"590":{"dur":1,"text":": Yeah, I think it's\nimportant for patients to"},"592":{"dur":2,"text":"be involved in all aspects\nof the study and that"},"595":{"dur":2,"text":"helps with recruitment\nand retention, because if"},"597":{"dur":3,"text":"patients feel ownership\nand they understand how"},"601":{"dur":2,"text":"the study is important to\nthem, important to people"},"603":{"dur":2,"text":"in the community, I think\nin rare diseases we have"},"606":{"dur":1,"text":"some very strong\ncommunity."},"607":{"dur":3,"text":"And so once patients\nunderstand how the data is"},"611":{"dur":2,"text":"going to be used, why it's\nso important, why it's"},"614":{"dur":1,"text":"important as you're\nplanning drug"},"616":{"dur":3,"text":"interventions, even if\nthere's not a drug on the"},"619":{"dur":2,"text":"horizon, how getting that\ninformation will help"},"621":{"dur":2,"text":"develop good clinical\ntrials and allow those"},"624":{"dur":2,"text":"trials to go more\nefficiently, then I think"},"627":{"dur":2,"text":"people are very motivated."},"629":{"dur":3,"text":"I think we have to keep in\nmind though, that even in"},"632":{"dur":2,"text":"a very motivated\npopulation, a population"},"634":{"dur":3,"text":"that's committed to seeing\nresearch moving forward in"},"638":{"dur":2,"text":"many rare diseases,\nfamilies are overwhelmed"},"640":{"dur":1,"text":"with the consequences\nof the rare diseases."},"643":{"dur":2,"text":"So they have doctor\nvisits, they have therapy"},"646":{"dur":3,"text":"visits, they have things\nthat have to go on at the"},"649":{"dur":1,"text":"school."},"650":{"dur":2,"text":"So it's important for the\npatient advocacy groups to"},"652":{"dur":1,"text":"give them a lot of\nopportunities to be"},"654":{"dur":3,"text":"involved, to come back if\nthey're overwhelmed with"},"658":{"dur":2,"text":"medical things now, maybe\nsix months from now they"},"661":{"dur":3,"text":"won't be overwhelmed, to\nshare data with them as we"},"664":{"dur":3,"text":"move along to keep them\nengaged and motivated to"},"668":{"dur":2,"text":"see the study through."},"671":{"dur":4,"text":": And Tim, I know you've\nbeen a participant in a"},"675":{"dur":4,"text":"natural history study and\nso you're very aware of"},"679":{"dur":2,"text":"the role of institutional\nreview boards in the"},"682":{"dur":2,"text":"conduct and making sure\nthat people know what"},"685":{"dur":1,"text":"they're getting into."},"686":{"dur":3,"text":"But there are, I think, in\naddition to the importance"},"690":{"dur":3,"text":"of informed consent, there\nare things that people"},"693":{"dur":2,"text":"should expect that\nare unexpected."},"696":{"dur":3,"text":"Maybe you can talk a\nlittle bit about your"},"700":{"dur":0,"text":"experience."},"701":{"dur":1,"text":"Absolutely."},"702":{"dur":3,"text":"I will first sort of echo\nwhat Theresa said, the"},"705":{"dur":3,"text":"importance of the patient\nadvocacy groups are"},"708":{"dur":4,"text":"Alpha-1 Antitrypsin\nOrganization, the Alpha-1"},"713":{"dur":3,"text":"Foundation is very active\nin reaching out to"},"716":{"dur":3,"text":"patients to get them\nmotivated to help them"},"720":{"dur":3,"text":"understand what studies\nmay be out there to"},"723":{"dur":1,"text":"include natural\nhistory studies."},"725":{"dur":5,"text":"Among the benefits that we\nall see, particularly in"},"733":{"dur":3,"text":"my disease, is the role of\nthe basic science that had"},"736":{"dur":3,"text":"been done for Alpha-1\nAntitrypsin lung disease"},"740":{"dur":3,"text":"and many people to include\nworking with NIH and FDA"},"744":{"dur":3,"text":"in the 80s, resulted in\ntherapies and successful"},"748":{"dur":3,"text":"therapies to stabilize\nour lung disease."},"752":{"dur":5,"text":"Now we're all being called\nupon to look at the"},"757":{"dur":3,"text":"Alpha-1 Antitrypsin\nliver disease to help"},"760":{"dur":4,"text":"researchers understand, as\nDr. Mulberg said, what are"},"764":{"dur":4,"text":"the mechanisms in this\ndisease, how do we"},"768":{"dur":1,"text":"understand disease\nprogression?"},"770":{"dur":5,"text":"So I'm involved in a five\nyear natural history study"},"775":{"dur":4,"text":"to look at the progression\nof disease over five"},"780":{"dur":0,"text":"years."},"781":{"dur":3,"text":"And when you, Richard,\nwhen you talk about"},"784":{"dur":3,"text":"unexpected, that's very\nimportant for patients"},"788":{"dur":3,"text":"going into a natural\nhistory study."},"791":{"dur":4,"text":"It starts with simple\nthings like how much"},"795":{"dur":3,"text":"paperwork, how many forms,\nhow many questionnaires,"},"798":{"dur":5,"text":"how much research do you\nhave to do to understand"},"804":{"dur":2,"text":"your family history?"},"806":{"dur":2,"text":"Is the center close\nto home or not?"},"808":{"dur":1,"text":"Do I have to travel?"},"810":{"dur":2,"text":"Is that travel going\nto be reimbursed?"},"812":{"dur":3,"text":"Will I have to stay\nlonger than expected?"},"816":{"dur":6,"text":"You have to socialize all\nof these kinds of things"},"822":{"dur":5,"text":"with the natural history\nstudy coordinator and with"},"828":{"dur":2,"text":"the principle\ninvestigator."},"831":{"dur":5,"text":"In my case, I actually had\na complication, in the"},"836":{"dur":4,"text":"part of the first year of\nthe study was to have a"},"840":{"dur":1,"text":"liver biopsy."},"842":{"dur":4,"text":"Now I have hyper inflated\nlungs, and unfortunately"},"846":{"dur":3,"text":"during the course of the\nlivery biopsy, my right"},"850":{"dur":3,"text":"lung got punctured, which\nthen caused me to suffer a"},"854":{"dur":1,"text":"deflated lung."},"855":{"dur":4,"text":"I didn't know that until I\narrived at home that the"},"860":{"dur":4,"text":"center was in middle\nAmerica, I flew home to"},"864":{"dur":4,"text":"Washington, D.C., my home,\nand when I got back to the"},"869":{"dur":4,"text":"ground, I realized that\nI was having a hard time"},"873":{"dur":1,"text":"breathing."},"874":{"dur":3,"text":"But the benefits of these\nstudies are very great."},"878":{"dur":3,"text":"In fact, even for me as\na patient, one of the"},"882":{"dur":2,"text":"conditions of this study\nis the patient gets all"},"885":{"dur":4,"text":"the results back."},"890":{"dur":3,"text":"So I am taking those\nresults to my medical"},"893":{"dur":3,"text":"community so they have\nthat data to help them as"},"897":{"dur":1,"text":"they work with me."},"899":{"dur":4,"text":"And then in my case, I\nreported back to the study"},"903":{"dur":2,"text":"my situation, shared with\nthem the data that I got"},"906":{"dur":3,"text":"from the hospital, so they\nnow have included that as"},"910":{"dur":3,"text":"an adverse result of their\nwork and have put in"},"914":{"dur":4,"text":"protocols that will\nbe attentive to the"},"918":{"dur":3,"text":"possibility of a\npneumothorax being"},"921":{"dur":1,"text":"created."},"923":{"dur":3,"text":"So they've taken that back\ninto the feedback for the"},"926":{"dur":1,"text":"study."},"927":{"dur":2,"text":": It was interesting for\nme to hear about the"},"929":{"dur":3,"text":"natural history study\nthat you're in, because I"},"933":{"dur":4,"text":"mostly fill out forms and\nsurveys for my husband and"},"937":{"dur":0,"text":"daughter."},"938":{"dur":2,"text":"I do a lot of it online,\nmost of it online."},"941":{"dur":4,"text":"And, you know, biopsies,\ndoctor visits, as part of"},"945":{"dur":2,"text":"the study are not\nsomething that we're"},"948":{"dur":2,"text":"accustomed to,\njust lots of forms."},"950":{"dur":2,"text":"And I'd say that for us,\nthe most complicated part"},"953":{"dur":6,"text":"so far has been trying\nto get films or CDs over"},"960":{"dur":3,"text":"images, you know, to\nbe part of the study."},"964":{"dur":1,"text":"That's been the\nhardest part."},"965":{"dur":2,"text":"Maybe in the future,\nthere might be, you know,"},"968":{"dur":1,"text":"tissues or something like\nthat that become part of"},"970":{"dur":1,"text":"the study."},"971":{"dur":1,"text":"But right now, we haven't\nhad to make special trips."},"973":{"dur":1,"text":"And we've been talking\nabout natural history"},"975":{"dur":2,"text":"studies as if they're a\nsingle animal, but I guess"},"977":{"dur":2,"text":"there are different types\nof natural history studies"},"980":{"dur":1,"text":"that are appropriate for\ndifferent purposes and"},"982":{"dur":0,"text":"different places."},"983":{"dur":2,"text":"Can we talk a little bit\nabout the differences in"},"986":{"dur":2,"text":"the types of studies\nand when they're most"},"989":{"dur":1,"text":"appropriate?"},"990":{"dur":1,"text":": When you think about\ndifferent kinds of natural"},"992":{"dur":1,"text":"history studies, I don't\nknow if we emphasized this"},"994":{"dur":3,"text":"enough, but there's\nbasically, there are kind"},"997":{"dur":1,"text":"of three ways to do it."},"999":{"dur":2,"text":"You can do a prospective\nstudy, you can do a"},"1002":{"dur":2,"text":"retrospective study, or\nyou can do what I think of"},"1005":{"dur":1,"text":"as a snapshot study."},"1007":{"dur":2,"text":"So a prospective study\nis one that's formally"},"1009":{"dur":2,"text":"organized and begins\nto collect data from a"},"1011":{"dur":0,"text":"certain point in time."},"1012":{"dur":2,"text":"It goes forward for\nwhatever the period of"},"1014":{"dur":1,"text":"time of collection that\nyou want to learn about"},"1016":{"dur":1,"text":"the natural history,\nprobably measured in"},"1018":{"dur":0,"text":"years."},"1020":{"dur":1,"text":"The retrospective we\ntalked about in terms of"},"1021":{"dur":1,"text":"trying to gather\ninformation that's already"},"1023":{"dur":1,"text":"collected, perhaps in\nmedical charts or other"},"1025":{"dur":3,"text":"kinds of documents that\nmay exist, and to try and"},"1029":{"dur":2,"text":"see if that can be used\nagainst the current"},"1032":{"dur":1,"text":"standards,\nwhat's going on."},"1033":{"dur":3,"text":"And then the snapshot is\ntrying to, this is not"},"1036":{"dur":2,"text":"what really happens, but\nI was thinking you got"},"1039":{"dur":2,"text":"everybody with a\nparticular rare disease in"},"1041":{"dur":3,"text":"the room on a given day,\nthey would be at all"},"1045":{"dur":2,"text":"different stages of the\ndisease, and you would"},"1048":{"dur":2,"text":"basically get information\nabout each of them and"},"1050":{"dur":3,"text":"their perception of their\ndisease and how they feel"},"1054":{"dur":2,"text":"and function and survive\nwith the disease."},"1056":{"dur":1,"text":"And you would get that\ninformation across a whole"},"1058":{"dur":2,"text":"group of people and that\nwould give you some"},"1060":{"dur":2,"text":"insights in terms of what\nhappens over the passage"},"1063":{"dur":1,"text":"of time as people are\naffected by these rare"},"1065":{"dur":2,"text":"diseases, they become\nmore symptomatic."},"1068":{"dur":2,"text":"But it's not as good as\nfollowing an individual"},"1070":{"dur":2,"text":"longitudinally, where you\nactually know specifically"},"1072":{"dur":1,"text":"what happened to that\nperson at all these"},"1074":{"dur":1,"text":"different data points."},"1076":{"dur":2,"text":": So who actually\nconducts these studies?"},"1079":{"dur":1,"text":"Who's responsible for\nfunding them, for"},"1081":{"dur":3,"text":"conducting them and\nassessing them?"},"1084":{"dur":4,"text":": I know with VHL, our\nadvocacy group administers"},"1089":{"dur":5,"text":"and possesses that data\nand funding is an issue"},"1096":{"dur":3,"text":"that we talk about\nin the group."},"1099":{"dur":2,"text":"We have a real rare\ndisease, so it's a small"},"1102":{"dur":1,"text":"group and fundraising is\nsomething that's difficult"},"1104":{"dur":5,"text":"and the administration\ndoes require funds."},"1110":{"dur":1,"text":"But we do it\nall ourselves."},"1111":{"dur":4,"text":"So Gayle, you basically\ninitiated the study and"},"1115":{"dur":2,"text":"funded it and\ndesigned it as well?"},"1118":{"dur":3,"text":"Right, the VHL Alliance\ndid that and they continue"},"1121":{"dur":3,"text":"to validate the\ndata as it comes in."},"1125":{"dur":1,"text":"They do that."},"1126":{"dur":3,"text":"Personally I just fill out\nthe surveys, but the group"},"1129":{"dur":2,"text":"does that."},"1132":{"dur":2,"text":"And that's what we've\ndone with Prader-Willie"},"1134":{"dur":1,"text":"Syndrome as well as."},"1136":{"dur":3,"text":"But it does take involving\nthe experts in the field"},"1140":{"dur":2,"text":"and you know, especially\nfor many rare diseases,"},"1142":{"dur":3,"text":"there's many systems that\nare affected, so you know"},"1146":{"dur":2,"text":"going to the experts\nand engaging them and"},"1148":{"dur":2,"text":"developing the right\nquestions to ask is"},"1151":{"dur":3,"text":"critical, and looking at\nthe data as it's coming in"},"1155":{"dur":2,"text":"and continuing to refine\nis also important."},"1157":{"dur":3,"text":"But funding is an issue\nand we, too, have funded"},"1161":{"dur":1,"text":"through grassroots\nfundraising efforts and"},"1163":{"dur":3,"text":"it's just been a priority\nfor our community to do"},"1167":{"dur":0,"text":"that."},"1168":{"dur":2,"text":"But it is always a\nchallenge to have the"},"1171":{"dur":1,"text":"adequate funding."},"1172":{"dur":3,"text":"So as the people who look\nat these studies afterward"},"1176":{"dur":4,"text":"and use them in assessing\ndrug applications, do you"},"1180":{"dur":2,"text":"find that there's\ndifferent styles or"},"1183":{"dur":1,"text":"different designs of\nstudies that work or"},"1185":{"dur":2,"text":"don't, or there's missing\ninformation or things that"},"1188":{"dur":2,"text":"advocacy organizations\nand others who do these"},"1190":{"dur":3,"text":"studies should be aware of\nprospectively before they"},"1194":{"dur":2,"text":"actually begin\ndesigning a study?"},"1198":{"dur":2,"text":"First of all, the FDA has\na critical role working"},"1201":{"dur":5,"text":"with the companies to help\nengage the patient groups"},"1212":{"dur":2,"text":"and the academic\nphysicians involved in the"},"1214":{"dur":1,"text":"care of these\nchildren and adults."},"1216":{"dur":2,"text":"Without the engagement of\nthe academics who are the"},"1218":{"dur":2,"text":"experts, I think the\npatient groups are not"},"1221":{"dur":2,"text":"going to be able to\naccomplish the task."},"1223":{"dur":2,"text":"We are very eager to\nwork with patient groups"},"1226":{"dur":1,"text":"through our\npatient engagement"},"1227":{"dur":1,"text":"responsibilities; also,\nwith the companies who"},"1229":{"dur":2,"text":"have a very important role\nto engage the patient"},"1232":{"dur":1,"text":"groups."},"1233":{"dur":1,"text":"But ultimately, the burden\nof collection of these"},"1235":{"dur":2,"text":"data, in my mind and my\nopinion, needs to involve"},"1238":{"dur":2,"text":"the academics early and\nreally needs to be a"},"1240":{"dur":1,"text":"global effort."},"1241":{"dur":2,"text":"As I think we've talked\nabout already, these are"},"1244":{"dur":2,"text":"diseases that are not just\ncentered in the United"},"1246":{"dur":3,"text":"States, and I would be\ncurious to understand how"},"1250":{"dur":2,"text":"my colleagues in the\npatient engagement area"},"1252":{"dur":3,"text":"have addressed that\nconcern about a global"},"1255":{"dur":3,"text":"disease that just doesn't\naffect, you know, US"},"1259":{"dur":0,"text":"children and adults."},"1260":{"dur":3,"text":"But to answer directly\nyour question, there are"},"1264":{"dur":2,"text":"often deficiencies in what\ncomes to us, not by the"},"1266":{"dur":3,"text":"fault of anyone, but it\nreally becomes an issue at"},"1270":{"dur":1,"text":"the stage of when\nit's initiated."},"1272":{"dur":1,"text":"Often natural history\nstudies are not started"},"1274":{"dur":2,"text":"early enough in the\nprocess of drug"},"1277":{"dur":2,"text":"development, which then\ncauses companies and"},"1279":{"dur":3,"text":"others to expedite often\ncollection of data that is"},"1283":{"dur":1,"text":"necessarily insufficient."},"1284":{"dur":3,"text":"But we thankfully have\nwonderful examples in our"},"1288":{"dur":3,"text":"legion of drugs that we've\napproved that have done it"},"1291":{"dur":3,"text":"very well and serve as\nvery good models for"},"1294":{"dur":1,"text":"others to follow."},"1296":{"dur":1,"text":"So natural history\nstudies, at least the way"},"1298":{"dur":4,"text":"I think about it, is\nthat you should begin to"},"1302":{"dur":2,"text":"initiate these very early\nin the drug development"},"1305":{"dur":1,"text":"process."},"1307":{"dur":1,"text":"You know, a lot of firms\nwait until they're ready"},"1309":{"dur":2,"text":"to do their definitive -\nwhat's called Phase Three"},"1311":{"dur":3,"text":"trial - and then they want\nto go out and start to do"},"1314":{"dur":1,"text":"this."},"1316":{"dur":1,"text":"Well, it takes a few years\nto get together some"},"1317":{"dur":2,"text":"natural history data and\nthey've kind of moved past"},"1320":{"dur":2,"text":"the point where they have\nthe time available to do"},"1322":{"dur":0,"text":"these studies."},"1323":{"dur":1,"text":"And that creates\na problem."},"1324":{"dur":2,"text":"If they'll move it back\nin the drug development"},"1327":{"dur":3,"text":"process once you have\na candidate drug, for"},"1331":{"dur":2,"text":"instance, something that\nhas gone through some"},"1333":{"dur":3,"text":"testing by basic\nscientists and information"},"1336":{"dur":2,"text":"is known about potential\nmechanisms of action, the"},"1339":{"dur":3,"text":"kind of infrastructure of\nscience that we look for"},"1342":{"dur":1,"text":"for drug development."},"1344":{"dur":4,"text":"At that point in time, I\nthink that the firm that's"},"1348":{"dur":3,"text":"doing the development\nor the patient advocacy"},"1351":{"dur":1,"text":"group, if they're doing\ndrug development, because"},"1353":{"dur":1,"text":"we're beginning to hear\nabout that as well, it's"},"1355":{"dur":2,"text":"time for them to really\nbuild some bridges from"},"1358":{"dur":3,"text":"the developer to the\nscientific community."},"1361":{"dur":2,"text":"So they can understand\nmore about what happens"},"1363":{"dur":1,"text":"with this disorder\nclinically to different"},"1365":{"dur":0,"text":"people."},"1366":{"dur":2,"text":"And if it's not, if it's\nnot a patient advocacy"},"1369":{"dur":2,"text":"group that's actually\ndoing the work, then"},"1371":{"dur":2,"text":"that's the time for the\nfirm to reach out, to make"},"1374":{"dur":3,"text":"connections to the people\nwho are actually the key"},"1377":{"dur":2,"text":"stakeholders in this whole\nprocess, because they'll"},"1380":{"dur":2,"text":"be able to help you\nunderstand what's"},"1382":{"dur":2,"text":"meaningful to them, what's\nclinically meaningful to"},"1384":{"dur":2,"text":"patients and families\nwho are affected by this"},"1387":{"dur":0,"text":"disease."},"1388":{"dur":2,"text":"And they'll also be able\nto help the firm as they"},"1391":{"dur":2,"text":"move into early testing\nwhere they want to recruit"},"1394":{"dur":2,"text":"subjects, and they'll be\nable to identify people"},"1397":{"dur":2,"text":"who are willing to\nparticipate as research"},"1399":{"dur":0,"text":"subjects in studies."},"1400":{"dur":3,"text":"And they'll be able to\nhelp in terms of other"},"1404":{"dur":2,"text":"ways, in terms of maybe\nretention in studies."},"1406":{"dur":1,"text":"Sometimes the resources\nfrom stakeholder groups"},"1408":{"dur":2,"text":"can pay for things like\ntaxi cabs, which sometimes"},"1412":{"dur":3,"text":"make a difference, get a\nperson from Point A across"},"1415":{"dur":2,"text":"town to Point B where\nthe clinical center is."},"1418":{"dur":1,"text":"It's a big deal."},"1419":{"dur":2,"text":"It's hard to do\nfor some people."},"1422":{"dur":3,"text":"So they can play really\nimportant roles that way."},"1425":{"dur":3,"text":"They can also help think\nabout trying to keep the"},"1428":{"dur":2,"text":"studies as open\nas possible."},"1430":{"dur":2,"text":"And just to explain\nthat a little bit."},"1433":{"dur":2,"text":"When you design a study\nyou usually have what are"},"1435":{"dur":2,"text":"called inclusion and\nexclusion criteria -"},"1438":{"dur":1,"text":"Inclusion criteria kind\nof the people who want to"},"1440":{"dur":0,"text":"bring into a trial."},"1441":{"dur":2,"text":"And the exclusion people\nyou want to keep out,"},"1444":{"dur":2,"text":"because maybe they have\nother complicated diseases"},"1447":{"dur":2,"text":"and it will be hard to\nunderstand what's going on"},"1449":{"dur":1,"text":"with the disease that\nyou're really interested"},"1451":{"dur":1,"text":"in."},"1452":{"dur":2,"text":"But a lot of these rare\ndiseases are very complex."},"1455":{"dur":4,"text":"And to not include really\na broad spectrum of people"},"1459":{"dur":3,"text":"who are affected early in\nthe game, I think, is a"},"1462":{"dur":1,"text":"place where the\nfirms fall down."},"1464":{"dur":2,"text":"They don't really get the\nfull, the full dimension"},"1467":{"dur":0,"text":"of the natural history."},"1468":{"dur":2,"text":"And if they'll pay\nattention to that earlier"},"1470":{"dur":2,"text":"in the drug development\nprocess, I think that"},"1473":{"dur":2,"text":"they'll have a much easier\ntime of it as they move"},"1475":{"dur":3,"text":"through sequential phases\nof drug development."},"1478":{"dur":2,"text":"There's a lot in what\nJonathan has offered here"},"1481":{"dur":3,"text":"and I do want to comment\non a couple of issues."},"1484":{"dur":2,"text":"One which, to underscore\nthe criticality of the"},"1487":{"dur":2,"text":"initiation of this and the\ninvolvement of the patient"},"1490":{"dur":5,"text":"engagement groups that\ncurrently 7,500 or so of"},"1496":{"dur":2,"text":"these diseases has been\ncharacterized to some"},"1498":{"dur":3,"text":"degree many of them, if\nnot the greatest majority,"},"1501":{"dur":3,"text":"don't have therapeutic\nagents targeted to"},"1504":{"dur":1,"text":"development of\nthese diseases."},"1506":{"dur":3,"text":"This is the time that\nthose physicians involved"},"1510":{"dur":3,"text":"in the care of these\nchildren, adults, affected"},"1513":{"dur":1,"text":"people, needs\nto be initiated."},"1515":{"dur":3,"text":"And not when the time of\na drug is currently in a"},"1519":{"dur":1,"text":"vial ready for\nhuman testing."},"1520":{"dur":2,"text":"In, I think our\nexperience, that's when I"},"1523":{"dur":3,"text":"think, as Dr. Goldsmith\nhas stated, it's often too"},"1526":{"dur":2,"text":"late and often results\nin trying to expedite"},"1529":{"dur":2,"text":"programs without full\nunderstanding of the"},"1531":{"dur":2,"text":"breadth of the\nheterogeneity of where"},"1534":{"dur":2,"text":"these diseases present\nthemselves differently in"},"1538":{"dur":1,"text":"children versus adults."},"1539":{"dur":2,"text":"The issues that are,\nyou're talking about"},"1541":{"dur":0,"text":"drawbacks."},"1542":{"dur":1,"text":"The drawbacks are not\ngetting started early"},"1544":{"dur":3,"text":"enough and of course, I'm\noversimplifying my role"},"1548":{"dur":1,"text":"because I'm not paying for\nthese studies and I'm not"},"1550":{"dur":2,"text":"coordinating them, so I'm\nnot underestimating the"},"1553":{"dur":2,"text":"critical importance\nof all of that."},"1556":{"dur":2,"text":"But it doesn't lessen to\nme the criticality of"},"1559":{"dur":3,"text":"doing it now, of getting\nthings started, and then"},"1562":{"dur":2,"text":"when the science comes\nto bear and a brilliant"},"1564":{"dur":2,"text":"scientist comes and says I\nhave a drug that I want to"},"1567":{"dur":3,"text":"test, we can accomplish\nexpediting the pathway"},"1571":{"dur":1,"text":"eventually, hopefully,\nto a drug approval."},"1573":{"dur":1,"text":"And you've asked\nfor examples."},"1575":{"dur":2,"text":"Well, you know two\nexamples, and there are"},"1577":{"dur":2,"text":"numerous that have used\nnatural history studies I"},"1580":{"dur":3,"text":"think successfully in\nhistorical controls, one"},"1583":{"dur":3,"text":"is a life threatening\ndisorder called Lysosomal"},"1586":{"dur":4,"text":"Acid Lipase Deficiency\nthat can present very"},"1591":{"dur":4,"text":"severely to fatal outcomes\nin newborns presenting"},"1595":{"dur":2,"text":"with swelling of their\nbody and low proteins and"},"1598":{"dur":1,"text":"liver failure."},"1599":{"dur":2,"text":"Babies often will die less\nthan the first year of"},"1602":{"dur":0,"text":"life."},"1603":{"dur":5,"text":"And this is a disease\nwhich is extremely rare,"},"1608":{"dur":2,"text":"with a disease prevalence\nof less than one in a"},"1611":{"dur":1,"text":"million, one in\nfive million."},"1613":{"dur":3,"text":"Yet, a therapy has\nbeen developed for the"},"1617":{"dur":2,"text":"treatment of this disease,\npredominantly in the"},"1620":{"dur":2,"text":"infant and older child\nform, which is much less"},"1622":{"dur":4,"text":"severe, called sebelipase\nor Kanuma, but for the"},"1627":{"dur":2,"text":"historical control\ndeveloped for the infant"},"1630":{"dur":3,"text":"approval of the indication\nrelied upon survival"},"1633":{"dur":1,"text":"analysis."},"1634":{"dur":3,"text":"And in this case, this was\na fatal disease that there"},"1638":{"dur":4,"text":"was ability to identify\na very large number of a"},"1642":{"dur":2,"text":"very severely affected\nnumber of infants, of"},"1645":{"dur":2,"text":"course we're talking about\na small population, but"},"1648":{"dur":3,"text":"was extremely useful for\nthe approvability of the"},"1652":{"dur":1,"text":"indication in infants."},"1653":{"dur":2,"text":"They used historical\ncontrol data based on"},"1656":{"dur":2,"text":"survival and\ngrowth failure."},"1658":{"dur":3,"text":"So that is to me, one of\nthe best recent examples"},"1662":{"dur":0,"text":"that we've had."},"1663":{"dur":3,"text":"Another recent example\nis one for a very rare"},"1666":{"dur":2,"text":"disease that causes very\nbrittle bones in infants"},"1669":{"dur":2,"text":"and children and adults\nthat comes in various"},"1672":{"dur":1,"text":"forms."},"1673":{"dur":2,"text":"But understanding how\nthis disease that affects"},"1675":{"dur":4,"text":"brittle bones, called\nhypophosphatasia, impacted"},"1680":{"dur":3,"text":"the way a child will walk,\nwas able to be assessed"},"1684":{"dur":3,"text":"retrospectively in a large\nway to be able to help the"},"1688":{"dur":2,"text":"approvability of this\ndrug, Strensiq, for this"},"1691":{"dur":1,"text":"indication."},"1692":{"dur":4,"text":"So these are just two\nexamples of a slew that we"},"1697":{"dur":2,"text":"have been gracefully been\nable to approve, not in"},"1699":{"dur":4,"text":"our division only, but\nin the FDA to develop"},"1704":{"dur":1,"text":"treatments for\nrare problems."},"1705":{"dur":2,"text":"And it seems that without\nthat kind of information"},"1707":{"dur":2,"text":"that's generated by these\nstudies, particularly if"},"1710":{"dur":2,"text":"they're started early,\nit would be very hard to"},"1713":{"dur":3,"text":"tease out what the effect\nof a proposed drug really"},"1717":{"dur":1,"text":"is, because you don't\nknow what the arc of the"},"1719":{"dur":2,"text":"underlying disease\nprogression would look"},"1721":{"dur":3,"text":"like, depending on age,\nstate of disease, all"},"1725":{"dur":2,"text":"kinds of environmental\nfactors that might impact"},"1727":{"dur":0,"text":"them."},"1728":{"dur":3,"text":"So they're very, very\nimportant studies to get"},"1731":{"dur":1,"text":"done and to get done\nearly, so that you have a"},"1733":{"dur":3,"text":"basis for assessing the\neffect of a proposed drug."},"1737":{"dur":2,"text":"And Gayle, you were\ntalking about funding and"},"1740":{"dur":2,"text":"fund raising and I don't\nknow if you can talk a"},"1743":{"dur":2,"text":"little about what does it\ntake to get one of these"},"1745":{"dur":3,"text":"studies off the ground and\nhow do you get the funds"},"1749":{"dur":1,"text":"to pull it off?"},"1750":{"dur":3,"text":"Right, so in our\norganization, it was"},"1754":{"dur":4,"text":"something that we\ntalked about for years."},"1758":{"dur":2,"text":"For a long time we talked\nabout developing a"},"1761":{"dur":2,"text":"registry and a natural\nhistory study."},"1764":{"dur":6,"text":"And I think for a while,\nwe were just too small to"},"1770":{"dur":2,"text":"fund it and to have the\nmanpower to even meet with"},"1773":{"dur":1,"text":"other experts to help."},"1774":{"dur":6,"text":"And I think that we got to\na point where we were just"},"1780":{"dur":2,"text":"large enough to support\nthe enterprise and to do"},"1783":{"dur":0,"text":"more fund raising."},"1784":{"dur":1,"text":"And it is very grassroots."},"1786":{"dur":2,"text":"It's a grassroots effort\nto do the fundraising."},"1789":{"dur":4,"text":"And then we got to a point\nwhere NORD also consulted"},"1793":{"dur":1,"text":"with us."},"1794":{"dur":3,"text":"And I wasn't really a part\nof that whole process."},"1798":{"dur":3,"text":"But I just knew that I\nthink it took a point in"},"1802":{"dur":1,"text":"our organization where\nwe were large enough to"},"1804":{"dur":0,"text":"support it."},"1805":{"dur":0,"text":"And you mentioned NORD."},"1806":{"dur":2,"text":"I know that NORD and\norganizations like NORD,"},"1809":{"dur":2,"text":"Genetic Alliance, for\nexample, do make available"},"1812":{"dur":2,"text":"platforms that\norganizations can use to"},"1814":{"dur":2,"text":"collect and analyze this\ninformation and get you"},"1817":{"dur":1,"text":"off the ground I guess."},"1819":{"dur":1,"text":"That helped us start."},"1820":{"dur":2,"text":"But I know there was a\nlot of work within the"},"1822":{"dur":2,"text":"organization\nbeyond that, too."},"1824":{"dur":2,"text":"And there continues to be."},"1827":{"dur":1,"text":"There's a lot of\ndifferent platforms, and I"},"1829":{"dur":1,"text":"think it's really\nimportant for patient"},"1831":{"dur":1,"text":"groups to do their\nhomework about the"},"1833":{"dur":2,"text":"different platforms and\nthe, you know, there's"},"1836":{"dur":2,"text":"many very good platforms,\nbut they are different."},"1838":{"dur":3,"text":"And so depending on the\nkind of data that you want"},"1842":{"dur":2,"text":"to get, the flexibility\nthat you need, the level"},"1844":{"dur":3,"text":"of support you need,\nwhether who's going to own"},"1847":{"dur":1,"text":"the data, all of these\nissues are different"},"1849":{"dur":1,"text":"across the different\nplatforms."},"1851":{"dur":3,"text":"So it is lot of work, but\nI think it's, especially"},"1855":{"dur":1,"text":"when these things are\ninitiated by the patient"},"1857":{"dur":2,"text":"groups, it's worth going\nout there and finding this"},"1860":{"dur":2,"text":"information about the\navailable platforms."},"1862":{"dur":2,"text":"And a lot of times that's\nnetworking with people at"},"1865":{"dur":2,"text":"various meetings\nthrough these umbrella"},"1867":{"dur":2,"text":"organizations, like NORD\nor Genetic Alliances, as"},"1870":{"dur":1,"text":"you've mentioned."},"1871":{"dur":3,"text":"But really looking at that\nvery carefully before you"},"1874":{"dur":3,"text":"kind of jump in, it's\nreally worth that effort."},"1878":{"dur":0,"text":"Right."},"1879":{"dur":1,"text":"And Theresa raised what\nI think is a really"},"1881":{"dur":2,"text":"interesting point of who\ndoes own that data, how do"},"1884":{"dur":3,"text":"you parlay that data with\ncompanies, with FDA?"},"1887":{"dur":4,"text":"And the other thing\nthat came to my mind is"},"1891":{"dur":0,"text":"confidentiality."},"1892":{"dur":2,"text":"How do people get assured\nof confidentiality,"},"1894":{"dur":3,"text":"because they're probably\nproviding a lot of very"},"1898":{"dur":1,"text":"personal and identifiable\ninformation?"},"1899":{"dur":2,"text":"And that's where, again,\nit's really important to"},"1901":{"dur":2,"text":"understand the platforms\nbecause there's different"},"1904":{"dur":1,"text":"levels of that and\ndifferent levels of"},"1906":{"dur":1,"text":"sophistication of that."},"1907":{"dur":2,"text":"And not only to understand\nthe platforms, but then to"},"1910":{"dur":3,"text":"be able to communicate\nthat back to your patient"},"1914":{"dur":1,"text":"community so that\neverybody in the community"},"1916":{"dur":3,"text":"understands, you know,\nwhat are, how is the data"},"1919":{"dur":2,"text":"secured, what level of\nprotection, those kinds of"},"1922":{"dur":0,"text":"issues."},"1923":{"dur":4,"text":"So it's very diverse out\nthere and people need to"},"1928":{"dur":1,"text":"look at that very\ncarefully, I think and"},"1930":{"dur":0,"text":"communicate that well."},"1931":{"dur":3,"text":"In the case of the\nAlpha-1 Foundation, we"},"1934":{"dur":4,"text":"have a fairly mature\norganization and process,"},"1938":{"dur":4,"text":"so we do have a medical\ncommittee and a research"},"1943":{"dur":5,"text":"committee, so that we're\nconstantly looking at and"},"1948":{"dur":3,"text":"partnering with the\nmedical community to look"},"1952":{"dur":3,"text":"at where are the areas\nthat we need to put our"},"1955":{"dur":1,"text":"research emphasis."},"1957":{"dur":5,"text":"And many of the sort of\nAlpha-1 experts across the"},"1963":{"dur":4,"text":"country, as Dr. Mulberg\nsaid, the international"},"1967":{"dur":4,"text":"aspect of bringing in\nAlpha-1 communities from"},"1972":{"dur":5,"text":"overseas also into I'll\ncall the brain trust and"},"1977":{"dur":4,"text":"where do we need\nto put our money?"},"1981":{"dur":4,"text":"And we generally try to\nfund, continue to fund"},"1987":{"dur":3,"text":"foundational science on\nall aspects of Alpha-1"},"1990":{"dur":1,"text":"Antitrypsin Deficiency."},"1992":{"dur":3,"text":"What more can we learn\nabout this disease that"},"1996":{"dur":4,"text":"may translate later in\ntranslational therapy."},"2001":{"dur":5,"text":"And then we also look at\nwhere can we put funding"},"2007":{"dur":5,"text":"for clinical research to\nhelp develop therapies?"},"2012":{"dur":5,"text":"We also have what we call\na philanthropic venture"},"2020":{"dur":4,"text":"capital company that also\nputs funding, and this is"},"2024":{"dur":1,"text":"a for-profit company,\nthat puts funding into"},"2026":{"dur":1,"text":"companies that are\ndeveloping potential"},"2028":{"dur":6,"text":"therapies that will\nbenefit the Alpha-1"},"2034":{"dur":4,"text":"Antitrypsin community."},"2039":{"dur":3,"text":"So we try to develop,\nI'll call it a pallet of"},"2043":{"dur":3,"text":"research, and then we use\nour national conferences,"},"2046":{"dur":1,"text":"we have regional\nconferences, our patient"},"2048":{"dur":1,"text":"support groups around\nthe country to encourage"},"2050":{"dur":1,"text":"Alpha-1 patients to be\ninvolved in whether it's a"},"2052":{"dur":1,"text":"natural history study,\nwhether it's a clinical"},"2054":{"dur":0,"text":"study."},"2055":{"dur":1,"text":"And we have, as both\nGayle and Theresa have"},"2057":{"dur":1,"text":"discussed, we have\nvery motivated patient"},"2059":{"dur":1,"text":"communities that want to\nparticipate and want to"},"2061":{"dur":5,"text":"participate in the hope\nthat it may help them, but"},"2075":{"dur":5,"text":"on the promise that it\nwill help also those who"},"2087":{"dur":5,"text":"follow; the future\nchildren that are born"},"2092":{"dur":1,"text":"with our rare diseases."},"2094":{"dur":1,"text":"How can we help them?"},"2095":{"dur":3,"text":"So you mentioned, you\nknow, collecting this"},"2098":{"dur":3,"text":"information and learning\nas you go along."},"2102":{"dur":2,"text":"Have you changed the\nnatural history study as"},"2105":{"dur":1,"text":"you've gone to accommodate\nthings that you're"},"2107":{"dur":2,"text":"learning, and are there\nplaces in FDA that patient"},"2109":{"dur":3,"text":"advocacy organizations can\ngo or anybody can go to"},"2113":{"dur":4,"text":"get advice on when and how\nand whether they should be"},"2118":{"dur":1,"text":"doing that?"},"2119":{"dur":3,"text":"I don't have an answer to\nthe question, whether what"},"2123":{"dur":3,"text":"we've found has changed\nthe course of the study"},"2127":{"dur":3,"text":"yet, but I think we've\nhad the first round of"},"2130":{"dur":1,"text":"patients."},"2131":{"dur":2,"text":"And that's a really good\nquestion that I would want"},"2134":{"dur":2,"text":"to ask the principle\ninvestigator."},"2136":{"dur":2,"text":"After the first round, are\nthey going to change how"},"2139":{"dur":6,"text":"they do things, have they\nfound results in the first"},"2145":{"dur":5,"text":"year interim that\nhave surprised them?"},"2151":{"dur":4,"text":"And does FDA offer advice?"},"2155":{"dur":2,"text":"I'm sure Jonathan\ncan answer this more"},"2158":{"dur":3,"text":"completely, but I will\noffer that I was curious"},"2161":{"dur":2,"text":"as to whether you all have\napproached the FDA through"},"2164":{"dur":3,"text":"the stages of developing\nyour registries\/natural"},"2167":{"dur":3,"text":"history studies to get\ncounsel and to ensure that"},"2171":{"dur":2,"text":"data collection was being\ndone in the most rigorous"},"2173":{"dur":3,"text":"way to kind of preclude\nsome of the problems that"},"2177":{"dur":3,"text":"often face that data are\noften collected and then,"},"2181":{"dur":2,"text":"unfortunately, without\nproper consultation with"},"2183":{"dur":2,"text":"us, which I think we, as\na division and I'm sure"},"2186":{"dur":2,"text":"throughout the FDA through\nthe Center for Drug"},"2188":{"dur":2,"text":"Evaluation Research for\nthe divisions that do"},"2191":{"dur":1,"text":"manage rare diseases."},"2192":{"dur":2,"text":"I believe I would speak on\ntheir behalf, saying we'd"},"2195":{"dur":3,"text":"rather hear from the\npatient engagement groups"},"2198":{"dur":2,"text":"who are doing this\ninnovative work early in"},"2201":{"dur":2,"text":"the process and offer the\nassistance that I know"},"2203":{"dur":2,"text":"Dr. Goldsmith can expand\nupon, because we want to"},"2206":{"dur":2,"text":"prevent problems on data\ncollection that isn't as"},"2209":{"dur":1,"text":"useful as it could be."},"2211":{"dur":1,"text":"Yeah."},"2213":{"dur":2,"text":"I think there are multiple\npotential layers for"},"2215":{"dur":1,"text":"consultation within\nthe Food and Drug"},"2217":{"dur":0,"text":"Administration."},"2218":{"dur":2,"text":"And so the Rare Diseases\nProgram that I'm the"},"2221":{"dur":2,"text":"Associate Director of\nwithin the Office of New"},"2223":{"dur":4,"text":"Drugs, we meet with people\nwho do drug development,"},"2228":{"dur":2,"text":"whether they be from\nthe corporate side or"},"2230":{"dur":2,"text":"sometimes from the\nstakeholder side, to try"},"2233":{"dur":2,"text":"and help them address some\nof these issues early in"},"2236":{"dur":3,"text":"the game, to try and\nmake sure that their"},"2239":{"dur":2,"text":"understanding of what's\nprobably needed down the"},"2242":{"dur":1,"text":"road is a good\nunderstanding."},"2243":{"dur":2,"text":"So informal consultations\nare always possible."},"2246":{"dur":1,"text":"We also have meetings."},"2247":{"dur":1,"text":"We usually also try and\nbring people to these"},"2249":{"dur":1,"text":"meetings from the\nreview divisions."},"2251":{"dur":1,"text":"So if your disease\nhappens to affect say, a"},"2253":{"dur":2,"text":"neurological problem, we\nhave the people from that"},"2255":{"dur":3,"text":"particular product review\ndivision come and they can"},"2259":{"dur":2,"text":"speak in that\nkind of a format."},"2261":{"dur":1,"text":"FDA has a cooperative\nagreement with the"},"2263":{"dur":2,"text":"National Organization for\nRare Disorders to use for"},"2266":{"dur":1,"text":"NORD, which is what it's\nknown as, for them to use"},"2268":{"dur":5,"text":"their registry platform to\ntry and create some new"},"2277":{"dur":2,"text":"natural history studies\nfor as many as another 10"},"2280":{"dur":3,"text":"or maybe 11 different\ndisease affected groups."},"2284":{"dur":1,"text":"And they have an\napplication process"},"2286":{"dur":2,"text":"actually that's ongoing\nnow, but there's this"},"2288":{"dur":3,"text":"cooperative agreement was\nthe result of interactions"},"2291":{"dur":3,"text":"between NORD and the\nCenter for Drug Evaluation"},"2295":{"dur":1,"text":"and Research."},"2296":{"dur":1,"text":"Jonathan, can you tell\nus a little bit about the"},"2298":{"dur":2,"text":"critical path innovation\nmeetings that FDA has been"},"2301":{"dur":0,"text":"holding?"},"2302":{"dur":1,"text":"I think this is a very\nimportant kind of"},"2304":{"dur":1,"text":"interaction between\nthe Food and Drug"},"2306":{"dur":2,"text":"Administration and\nregulated industry that's"},"2309":{"dur":3,"text":"been going on for\nseveral years now."},"2312":{"dur":4,"text":"I think it's reached a\nfairly mature stage."},"2317":{"dur":4,"text":"These are discussions not\nabout the development of a"},"2321":{"dur":3,"text":"particular drug, but\nthey're about technology"},"2325":{"dur":1,"text":"and science."},"2326":{"dur":3,"text":"But those techniques of\ntechnology and science are"},"2329":{"dur":3,"text":"things that actually often\nresult in new drugs."},"2332":{"dur":1,"text":"They're part of the\ninfrastructure."},"2334":{"dur":1,"text":"They range from things\nlike measurement of a"},"2336":{"dur":3,"text":"particular substance\nin a human, to actually"},"2340":{"dur":2,"text":"different classes of\ndrugs, and they interact"},"2343":{"dur":1,"text":"with the human genome\nin a certain way."},"2345":{"dur":4,"text":"And it's a chance for\nFDA investigators, our"},"2349":{"dur":3,"text":"scientists, to speak with\nscientists from regulated"},"2353":{"dur":2,"text":"industry in a very open\nand interactive way,"},"2356":{"dur":2,"text":"because sometimes there\nare important questions of"},"2359":{"dur":2,"text":"a regulatory nature we\nneed to have answered."},"2361":{"dur":2,"text":"And they actually have the\nwherewithal to do that."},"2364":{"dur":1,"text":"And vice versa."},"2365":{"dur":2,"text":"We may have the scientific\nbasis to answer issues"},"2367":{"dur":3,"text":"that they're interested in\nthat really pertain to the"},"2371":{"dur":2,"text":"broad area of drug\ndevelopment, not to a"},"2373":{"dur":1,"text":"particular product at all."},"2375":{"dur":2,"text":"And how do people find\nout or initiate those"},"2378":{"dur":0,"text":"meetings?"},"2379":{"dur":1,"text":"Would they go to the FDA\nwebsite, for example?"},"2381":{"dur":3,"text":"Office of Translational\nSciences, OTS, within the"},"2384":{"dur":2,"text":"Food and Drug\nAdministration, organizes"},"2387":{"dur":1,"text":"those meetings."},"2388":{"dur":2,"text":"And there's a formal\nprocess, there's an"},"2390":{"dur":2,"text":"application process\nand then there's an"},"2392":{"dur":1,"text":"arrangement process."},"2394":{"dur":4,"text":"It's held as a face to\nface meeting at the FDA"},"2398":{"dur":3,"text":"facilities in Silver\nSpring, Maryland."},"2402":{"dur":2,"text":"So Jonathan, can patient\nadvocacy organizations"},"2404":{"dur":3,"text":"access those critical path\ninnovation meetings to"},"2408":{"dur":4,"text":"talk to FDA about\nnatural history studies?"},"2413":{"dur":2,"text":"Yeah, I think that's a\nvery appropriate use of"},"2415":{"dur":0,"text":"the mechanism."},"2416":{"dur":1,"text":"I didn't emphasize\nthat enough."},"2418":{"dur":2,"text":"But it's certainly an\navenue that people could"},"2420":{"dur":1,"text":"explore."},"2421":{"dur":3,"text":"I would encourage the\nstakeholder organizations"},"2425":{"dur":1,"text":"to seek that out."},"2427":{"dur":4,"text":"We've talked about how\n7,500 rare diseases have"},"2434":{"dur":1,"text":"been isolated."},"2436":{"dur":3,"text":"Not all of them have\npatient advocacy"},"2439":{"dur":1,"text":"organizations."},"2440":{"dur":5,"text":"How does a group that\nwants to coalesce learn"},"2446":{"dur":3,"text":"how to navigate\nthe FDA labyrinth?"},"2450":{"dur":2,"text":"How do we plug into it?"},"2453":{"dur":3,"text":"This is probably the fifth\nengagement I've had with"},"2456":{"dur":1,"text":"FDA."},"2457":{"dur":3,"text":"I have no idea what your\nwiring diagram looks like,"},"2461":{"dur":4,"text":"how I would find out that\nthere are these meetings"},"2465":{"dur":4,"text":"that I can go to or I can\nfind someone who can help"},"2469":{"dur":2,"text":"review my natural\nhistory study design."},"2472":{"dur":1,"text":"How do I navigate?"},"2473":{"dur":2,"text":"What a great question,\nbecause our office, the"},"2475":{"dur":5,"text":"Office of Health and\nConstituent Affairs, has a"},"2481":{"dur":5,"text":"website, which is the\nFor Patients website at"},"2487":{"dur":1,"text":"<u>www.fda.gov\n<http:\/\/www.fda.gov><\/u> ."},"2489":{"dur":3,"text":"And on that website, we\nlist all the upcoming"},"2492":{"dur":2,"text":"meetings that people\ncan participate in."},"2495":{"dur":3,"text":"We list the opportunities\nfor comment."},"2498":{"dur":2,"text":"So not very many people\nread the federal register"},"2501":{"dur":2,"text":"every day, but actually\nwe go through the federal"},"2503":{"dur":1,"text":"register, pick out things\nthat are important to"},"2505":{"dur":3,"text":"patients, and list them,\nso you know when meetings"},"2508":{"dur":2,"text":"are coming up and when\npublic comment is being"},"2511":{"dur":1,"text":"sought."},"2512":{"dur":3,"text":"But the office itself is a\npoint of entry for you to"},"2516":{"dur":2,"text":"come in, we're happy to\nmeet with people, talk"},"2518":{"dur":2,"text":"about how FDA is put\ntogether, how it's"},"2521":{"dur":2,"text":"arranged and how we can\nset meetings up for"},"2523":{"dur":3,"text":"patients and advocates to\ntalk to people at FDA and"},"2527":{"dur":2,"text":"learn what's the best\napproach for moving"},"2529":{"dur":1,"text":"forward."},"2530":{"dur":2,"text":"And we've been using the\nFDA as a patient group"},"2533":{"dur":2,"text":"several times and\nit's always been very"},"2535":{"dur":2,"text":"responsive and you know,\nwe've invited FDA to some"},"2538":{"dur":5,"text":"of our meetings and many\nhave come and it's been"},"2543":{"dur":1,"text":"very good."},"2544":{"dur":2,"text":"But it is, we do usually\ngo through your office."},"2547":{"dur":4,"text":"So from the patient\nadvocacy perspective, one"},"2551":{"dur":1,"text":"of the things I'm\nwondering is, you guys"},"2553":{"dur":1,"text":"have all had experience\nwith natural history"},"2555":{"dur":4,"text":"studies and are there\npitfalls, challenges,"},"2560":{"dur":2,"text":"things that you think\nyou've encountered along"},"2562":{"dur":2,"text":"the way that would be\nhelpful for people who are"},"2565":{"dur":2,"text":"following down that same\npath, things that would"},"2568":{"dur":2,"text":"smooth the path out a\nlittle bit by not having"},"2570":{"dur":2,"text":"to make the same mistakes\nthat might have been"},"2573":{"dur":3,"text":"encountered in never\nhaving done it and trying"},"2577":{"dur":3,"text":"to create a natural\nhistory study?"},"2580":{"dur":3,"text":"Well, I can comment\nfrom the perspective of"},"2584":{"dur":3,"text":"somebody who's provided\ndata as a caregiver more"},"2588":{"dur":3,"text":"than on the\ndevelopment side."},"2592":{"dur":2,"text":"But it is a time consuming\nprocess to go through as a"},"2595":{"dur":5,"text":"patient or caregiver and I\nthink that if an advocacy"},"2603":{"dur":3,"text":"group makes that clear,\nbut also makes it clear to"},"2607":{"dur":4,"text":"patients and caregivers\nthat they can provide a"},"2611":{"dur":1,"text":"little bit of data at a\ntime, I always like to"},"2613":{"dur":3,"text":"say, don't let the great\nbe the enemy of the good."},"2616":{"dur":1,"text":"You can do a little\nbit at a time."},"2618":{"dur":1,"text":"If there's a question\nthat's difficult to"},"2620":{"dur":2,"text":"answer, you can skip\nit and come back."},"2622":{"dur":2,"text":"I think that\nwould be helpful."},"2625":{"dur":3,"text":"I know with our study,\nthere are follow ups where"},"2629":{"dur":4,"text":"you fill out the same\nquestionnaires at"},"2633":{"dur":0,"text":"intervals."},"2634":{"dur":2,"text":"And those questionnaires\nare the same"},"2637":{"dur":2,"text":"questionnaires you filled\nout in the past but they"},"2640":{"dur":1,"text":"don't have the information\nthat you've put in."},"2642":{"dur":3,"text":"And I think they were\ndesigned that way so that"},"2645":{"dur":3,"text":"people would not be\ntempted not to think about"},"2649":{"dur":3,"text":"the questions and\nnot to update them."},"2652":{"dur":2,"text":"But it's extra time\nconsuming and frustrating"},"2655":{"dur":1,"text":"at times."},"2656":{"dur":2,"text":"So those are the pitfalls\nfrom my perspective, but"},"2658":{"dur":4,"text":"I'm not developing\nthe survey."},"2663":{"dur":1,"text":"We hear that and we've\nheard that a lot."},"2665":{"dur":1,"text":"I mean one thing we've\nreally learned was that"},"2667":{"dur":3,"text":"patients are really\ncommitted, our families"},"2670":{"dur":1,"text":"are."},"2671":{"dur":1,"text":"But it is really hard and\nwe want to make it as easy"},"2673":{"dur":1,"text":"as easy as it can be for\nthem, so we want to give"},"2675":{"dur":2,"text":"them multiple avenues\nto complete these long"},"2678":{"dur":1,"text":"surveys, which they're\ngoing to complete."},"2680":{"dur":3,"text":"And not everybody is so\nwell versed in what a"},"2684":{"dur":1,"text":"consent is and\nwhat an assent is."},"2686":{"dur":3,"text":"So our individuals with\nPWS oftentimes have"},"2689":{"dur":2,"text":"intellectual disabilities\nso there's an assent"},"2691":{"dur":2,"text":"process in addition\nto the consent."},"2694":{"dur":2,"text":"And you know people don't\nknow that much about that."},"2697":{"dur":1,"text":"And it can be complicated."},"2698":{"dur":2,"text":"So we learned pretty\nquickly that we needed"},"2701":{"dur":2,"text":"multiple ways to\ncommunicate that to the"},"2703":{"dur":1,"text":"families."},"2705":{"dur":2,"text":"So we made a video that\nwill walk you through the"},"2708":{"dur":2,"text":"process of the consent and\nassent and registration."},"2710":{"dur":2,"text":"And we have a\ndownloadable document."},"2713":{"dur":2,"text":"And we set up a Facebook\npage, a closed Facebook"},"2715":{"dur":2,"text":"page, so people could, if\nthey wanted to, join it"},"2718":{"dur":2,"text":"and then ask questions if\nthey had questions that"},"2721":{"dur":0,"text":"popped up."},"2722":{"dur":1,"text":"And we have webinars\nwhere you can call in."},"2724":{"dur":3,"text":"So we have tried to make\nmultiple ways for people"},"2728":{"dur":4,"text":"to be drawn in, and\nencourage them along the"},"2732":{"dur":3,"text":"way because sometimes\npeople, we can, which is"},"2736":{"dur":2,"text":"nice, do some of the\nsurveys, but not all of"},"2738":{"dur":1,"text":"them, but then bringing\nthem back to complete the"},"2740":{"dur":1,"text":"surveys is the challenge,\nso keeping people"},"2742":{"dur":0,"text":"motivated."},"2743":{"dur":4,"text":"So if you put a lot of\nthought into that at the"},"2748":{"dur":1,"text":"front end, making it as\neasy as possible for"},"2750":{"dur":1,"text":"people to complete these\nnatural history studies,"},"2752":{"dur":1,"text":"whether they be surveys on\nthe web or whether they be"},"2754":{"dur":2,"text":"going to a clinical place\nand doing a trial and get"},"2756":{"dur":2,"text":"the patient input on how\nto make that as easy."},"2759":{"dur":3,"text":"I think it's a huge plus\nfor getting things done."},"2763":{"dur":3,"text":"I think that\ncommunication is very"},"2767":{"dur":1,"text":"important."},"2768":{"dur":4,"text":"I think having the patient\nadvocacy organization with"},"2773":{"dur":2,"text":"patients work with a\nprinciple investigator in"},"2775":{"dur":4,"text":"the design phase is really\nimportant to make sure"},"2780":{"dur":4,"text":"that everyone understands\nwhat's needed, how it's"},"2785":{"dur":3,"text":"needed, what the impact is\non a patient, rather than"},"2789":{"dur":2,"text":"having any particular\nparty going off into their"},"2791":{"dur":3,"text":"own little cubby, but have\neverybody looking at that."},"2795":{"dur":1,"text":"Can that questionnaire\nbe done in a phased way?"},"2797":{"dur":6,"text":"Can the clinical work be\ndone close to home or do"},"2803":{"dur":5,"text":"you have to travel\nare important issues."},"2812":{"dur":4,"text":"And as I always say,\nprovide feedback to that"},"2816":{"dur":4,"text":"patient, keep them\nmotivated and even"},"2821":{"dur":1,"text":"rewards."},"2822":{"dur":2,"text":"Even if you say, god that\nwas a really, you really"},"2825":{"dur":2,"text":"did a really great job on\nthat questionnaire, that"},"2827":{"dur":1,"text":"was very, very\nhelpful to us."},"2829":{"dur":1,"text":"So there's a\nfeedback loop."},"2831":{"dur":3,"text":"So that all of it is\nto engage your patient"},"2835":{"dur":3,"text":"community to help them\nhelp the principle"},"2838":{"dur":3,"text":"investigator have a\nsuccessful study, do all"},"2842":{"dur":2,"text":"those things that we've\ntalked about, build that"},"2845":{"dur":3,"text":"foundational science and\nthen be able to take the"},"2848":{"dur":2,"text":"next steps into\ndevelopment of drugs and"},"2851":{"dur":1,"text":"therapy."},"2852":{"dur":4,"text":"If we can, as patients,\nsee that continuum, we"},"2857":{"dur":2,"text":"will be highly motivated\nand keep that feedback"},"2860":{"dur":0,"text":"loop going."},"2861":{"dur":2,"text":"It's very, very important."},"2864":{"dur":2,"text":"One point that has been\nbrought up to some degree,"},"2867":{"dur":2,"text":"but I think is worth\ndiscussing a little bit"},"2869":{"dur":1,"text":"more is the\ndiversity issue."},"2872":{"dur":3,"text":"I think we want a good\nrepresentation of our"},"2875":{"dur":2,"text":"disorder and we're\nthinking of diversity in"},"2877":{"dur":1,"text":"all sorts of ways."},"2879":{"dur":2,"text":"So obviously, ethnic\nand racial diversity,"},"2881":{"dur":4,"text":"socio-economic diversity,\nbut also age diversity,"},"2885":{"dur":2,"text":"because like many rare\ndiseases disorders in"},"2887":{"dur":2,"text":"children is very different\nand sometimes opposite of"},"2890":{"dur":4,"text":"what it is in adults, so\nwe want to make sure we're"},"2894":{"dur":2,"text":"reaching both parents of\nyoung children who are"},"2897":{"dur":2,"text":"often more engaged, and\nthen parents of older"},"2900":{"dur":3,"text":"children who may be a\nlittle bit harder to reach"},"2904":{"dur":1,"text":"and then the\nentire spectrum."},"2905":{"dur":3,"text":"So kids who are doing\nreally well may not be as"},"2909":{"dur":2,"text":"engaged in the patient\nadvocacy community because"},"2912":{"dur":2,"text":"their kids are\ndoing really well."},"2914":{"dur":3,"text":"And kids who are doing\nreally poorly may have so"},"2917":{"dur":3,"text":"many medical issues that\nthey're not as engaged as"},"2920":{"dur":0,"text":"well."},"2921":{"dur":1,"text":"So I think from the\npatient advocacy group,"},"2923":{"dur":1,"text":"it's very important to\nkeep that in mind as"},"2925":{"dur":2,"text":"you're developing these\nstrategies to reach out"},"2927":{"dur":0,"text":"into the population."},"2928":{"dur":3,"text":"Social media's great, but\nit really is a skewed"},"2931":{"dur":2,"text":"population compared to\nyour entire patient"},"2933":{"dur":1,"text":"population."},"2934":{"dur":2,"text":"So thinking of different\nways to be reaching the"},"2937":{"dur":1,"text":"very diverse patient\npopulation, educating"},"2939":{"dur":2,"text":"people why it's important\nto see the most difficult"},"2942":{"dur":3,"text":"cases, as well as the best\ncase scenario, so that we"},"2946":{"dur":2,"text":"can really understand\nthe full spectrum of the"},"2948":{"dur":1,"text":"natural history."},"2949":{"dur":2,"text":"I think Theresa's point is\ncritical in that we have"},"2953":{"dur":3,"text":"to understand the way this\ndisease presents, both"},"2956":{"dur":3,"text":"from the youngest of child\nto the eldest of adult."},"2959":{"dur":2,"text":"Without understanding\nthat, I don't see, at"},"2962":{"dur":2,"text":"least from our experience,\nthat's when the"},"2965":{"dur":2,"text":"interpretability of the\ndata from a certain"},"2967":{"dur":3,"text":"discerning drug effect\non an outcome is very"},"2970":{"dur":2,"text":"difficult to make and then\ntrial design becomes even"},"2973":{"dur":1,"text":"more important\nand critical."},"2975":{"dur":2,"text":"So I think the point\nthat Theresa, should be"},"2977":{"dur":2,"text":"underscored is that\ngetting as much"},"2979":{"dur":2,"text":"information about the\ndisease, understanding"},"2982":{"dur":3,"text":"what it's doing to every\npatient that one can"},"2985":{"dur":3,"text":"gather, and again, I would\njust like to reiterate and"},"2989":{"dur":3,"text":"I'm trying to understand\nabout how patient groups"},"2992":{"dur":3,"text":"try to recruit potential\nparticipants in the study,"},"2996":{"dur":2,"text":"because that in itself\ncould be a bias"},"2998":{"dur":1,"text":"population."},"2999":{"dur":3,"text":"So I'm curious to know how\nyou engage, what is your"},"3003":{"dur":3,"text":"scope and breadth of\nreaching out to your"},"3006":{"dur":0,"text":"population?"},"3007":{"dur":1,"text":"You know, we took the\nlow hanging fruit first,"},"3009":{"dur":2,"text":"right, through social\nmedia, which is great and"},"3011":{"dur":1,"text":"was very effective."},"3012":{"dur":1,"text":"But now we're doing the\nharder work which is going"},"3013":{"dur":2,"text":"through clinics, going\nthrough local support"},"3016":{"dur":3,"text":"groups, you know, reaching\nout in ... we're trying"},"3019":{"dur":2,"text":"out a bunch of different\nways through residential"},"3022":{"dur":3,"text":"homes that specialize with\npeople with Prader Willi"},"3025":{"dur":1,"text":"Syndrome."},"3026":{"dur":4,"text":"So we're in that sort of\nphase of just testing out"},"3031":{"dur":4,"text":"ways, but we realized\npretty quickly that we"},"3035":{"dur":4,"text":"were getting a very, a\nwonderful population, but"},"3040":{"dur":2,"text":"not a representative\npopulation."},"3042":{"dur":1,"text":"I think finding those\npatients who are"},"3044":{"dur":2,"text":"asymptomatic is\nso important."},"3046":{"dur":4,"text":"What makes that patient\nnot present those"},"3051":{"dur":3,"text":"symptoms?"},"3055":{"dur":1,"text":"That may be a pointer\ntowards therapies or"},"3057":{"dur":0,"text":"drugs."},"3058":{"dur":4,"text":"I mean, we have the same\nissue with the Alpha-1"},"3062":{"dur":0,"text":"liver disease."},"3063":{"dur":2,"text":"Some have it, some don't."},"3066":{"dur":3,"text":"Why don't some of\nthem not get it?"},"3070":{"dur":5,"text":"What are those\nbiochemical, those genetic"},"3076":{"dur":5,"text":"pointers that protect the\none and not the other?"},"3081":{"dur":2,"text":"Why are some Alphas\ntotally asymptomatic?"},"3084":{"dur":3,"text":"Have no lung disease,\nno liver disease?"},"3087":{"dur":3,"text":"Those are the ones that\nyou also, I want to bottle"},"3090":{"dur":1,"text":"that genie."},"3092":{"dur":3,"text":"I want to understand that\nand find those people and"},"3095":{"dur":5,"text":"those are the ones that\nare hardest to find."},"3101":{"dur":2,"text":"One other question that I\nhad is, do you find it's"},"3104":{"dur":2,"text":"difficult to get\npeople interested in"},"3107":{"dur":2,"text":"participating in these\nstudies given the"},"3110":{"dur":3,"text":"challenges that people\nface in data entry,"},"3113":{"dur":4,"text":"showing up at study sites\nat regular intervals?"},"3117":{"dur":1,"text":"Is it difficult to get\npeople to joint those"},"3119":{"dur":2,"text":"studies and then retain\npeople in those studies?"},"3122":{"dur":2,"text":"I think it's challenging."},"3125":{"dur":2,"text":"Yes, again as we've\nsaid, there are so many"},"3128":{"dur":2,"text":"pressures on a family\nthat's dealing with a rare"},"3131":{"dur":3,"text":"disorder that it's really\nimportant to try to make"},"3134":{"dur":3,"text":"it as easy as possible\nfor those individuals and"},"3138":{"dur":2,"text":"communicate back to them\nas much as possible."},"3141":{"dur":4,"text":"But even at that, I mean\nday to day life sometimes,"},"3145":{"dur":1,"text":"you know, can be\noverwhelming."},"3147":{"dur":2,"text":"So I think...with these\nrare disorders, we're kind"},"3150":{"dur":2,"text":"of a family for a long\nterm so again, having"},"3152":{"dur":2,"text":"multiple opportunities for\nthem to come back and you"},"3155":{"dur":1,"text":"know, participate, maybe\nthey can't participate now"},"3157":{"dur":1,"text":"but maybe later,\nand keeping those"},"3159":{"dur":2,"text":"possibilities open is\nreally important to"},"3162":{"dur":1,"text":"maintaining that."},"3164":{"dur":1,"text":"Yeah, I think about\njoining the study though"},"3166":{"dur":9,"text":"and I delayed a little bit\nincluding my daughter and"},"3175":{"dur":7,"text":"in that case I thought\nwell, you know, do I want"},"3182":{"dur":3,"text":"to do this for her, how's\nshe going to feel about it"},"3186":{"dur":1,"text":"when she's a teenager?"},"3187":{"dur":1,"text":"How is she going to feel\nabout it when she's an"},"3189":{"dur":1,"text":"adult?"},"3191":{"dur":2,"text":"Now when she turns 18, she\nneeds to consent on her"},"3193":{"dur":2,"text":"own in order for her\ninformation to remain in"},"3196":{"dur":1,"text":"that database."},"3198":{"dur":4,"text":"But ultimately and\nespecially after hearing"},"3202":{"dur":2,"text":"you guys talk, she's a\ngreat source of data"},"3205":{"dur":3,"text":"because she's young\nand she's relatively"},"3208":{"dur":1,"text":"asymptomatic\nat this point."},"3210":{"dur":4,"text":"And ultimately knowing\nthat she'd have to consent"},"3214":{"dur":3,"text":"herself at 18 and that she\ndidn't have to keep data"},"3218":{"dur":2,"text":"as part of the study if\nshe didn't want to, I did"},"3220":{"dur":0,"text":"include her."},"3221":{"dur":2,"text":"But that was a barrier\nfor me at first."},"3224":{"dur":1,"text":"And we do try to make,\nyou know, as much as you"},"3226":{"dur":2,"text":"can make it useful for the\npatient, so you mentioned,"},"3229":{"dur":3,"text":"Tim, you get the data back\nthat you can share with"},"3233":{"dur":0,"text":"your medical team."},"3234":{"dur":3,"text":"For our families, it's\na place to store all of"},"3238":{"dur":2,"text":"their medical information\nthat they can then print"},"3241":{"dur":2,"text":"off, you know all the\ndifferent specialists"},"3243":{"dur":2,"text":"they've seen, they can\nprint all that information"},"3246":{"dur":3,"text":"off and take it to their\ngeneral practitioner so"},"3249":{"dur":2,"text":"they have a big\npicture view."},"3251":{"dur":1,"text":"So we try to make sure\nthere's some value back to"},"3253":{"dur":2,"text":"the patient that will\nhopefully be helpful to"},"3256":{"dur":1,"text":"keep them engaged as well."},"3258":{"dur":1,"text":"Right."},"3259":{"dur":2,"text":"Our community is motivated\nbut at the same time, like"},"3262":{"dur":2,"text":"in the case of my\nstudy, it's a five year"},"3264":{"dur":4,"text":"commitment that you're\ngoing to be in this study"},"3269":{"dur":3,"text":"for five years and that\nyou will continue to have"},"3272":{"dur":1,"text":"the kind of testing\nthat we have."},"3274":{"dur":5,"text":"It's important and it will\nhopefully help research"},"3280":{"dur":5,"text":"for therapies, but I've\nhad other colleagues who"},"3286":{"dur":2,"text":"have had also adverse\neffects and they're going"},"3289":{"dur":1,"text":"like, gee, am I going to\ngo back the second year?"},"3291":{"dur":2,"text":"This was scary for me."},"3294":{"dur":4,"text":"That's where the reward,\nthat's where the feedback"},"3298":{"dur":4,"text":"is so important from the\npatient advocacy group,"},"3303":{"dur":5,"text":"helping make it easy, the\nfinancial issues are some."},"3308":{"dur":3,"text":"I paid about twice as much\nas I was reimbursed for"},"3312":{"dur":2,"text":"the study that I was at."},"3314":{"dur":4,"text":"I had to travel half way\nacross the country, stay"},"3319":{"dur":5,"text":"in a hotel for a couple\nof days, taxi cabs you"},"3324":{"dur":1,"text":"mentioned."},"3325":{"dur":5,"text":"But that's where the\nreward comes in where the"},"3330":{"dur":1,"text":"PI feeds back, where\npatient advocacy groups"},"3332":{"dur":1,"text":"say thank you to those\npatients that are doing"},"3334":{"dur":4,"text":"this work, because it's\ngoing to get us closer to"},"3339":{"dur":9,"text":"a cure for all of these\n7,500 rare diseases that"},"3348":{"dur":1,"text":"we have in this country."},"3350":{"dur":3,"text":"When you add all that up,\nthat's a lot of people"},"3353":{"dur":2,"text":"across this country\nwho are affected."},"3356":{"dur":2,"text":"I think it's been a\nterrific discussion."},"3359":{"dur":3,"text":"I hope it adds value to\npeople who are watching to"},"3362":{"dur":2,"text":"understand what natural\nhistory studies are, what"},"3365":{"dur":2,"text":"the challenges are,\nwhat the rewards are."},"3367":{"dur":4,"text":"And I think there's a lot\nto be said in all of those"},"3372":{"dur":0,"text":"areas."},"3373":{"dur":2,"text":"And as always, people\ncan contact the FDA."},"3375":{"dur":3,"text":"You can contact us through\nour website or call our"},"3379":{"dur":2,"text":"office, the Office of\nHealth and Constituent"},"3382":{"dur":1,"text":"Affairs."},"3383":{"dur":2,"text":"Thank you all very, very\nmuch for participating."},"3387":{"dur":2,"text":"We hope you found this\nprogram to be useful and"},"3390":{"dur":2,"text":"have learned more about\nthe nuts and bolts of"},"3392":{"dur":2,"text":"natural history studies,\nwhat they are, why they're"},"3395":{"dur":2,"text":"so critical for\neffectively developing"},"3398":{"dur":2,"text":"products for rare\ndiseases, and the"},"3400":{"dur":1,"text":"important role that\npatients and patient"},"3402":{"dur":2,"text":"advocacy groups can play."},"3405":{"dur":2,"text":"By working together to\nbuild a solid scientific"},"3407":{"dur":3,"text":"foundation we can greatly\nspeed the development of"},"3410":{"dur":2,"text":"products for the many\nmillions of rare disease"},"3413":{"dur":2,"text":"patients who need them."},"3415":{"dur":2,"text":"Thank you."}}